Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Investor Presentation (June 2025)
27 slides from Legend Biotech's investor presentation, Jun 6, 2025
Slide 1: Legend Biotech Corporate Presentation June 2025
1 Legend Biotech CORPORATE PRESENTATION JUNE 2025
Slide 2: Disclaimer
2 Disclaimer This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in
Slide 3: Legend Biotech – Transforming Cancer Care
3 11 Pipeline Programs in Hematologic Malignancies, Solid Tumors, and Autoimmune Diseases Legend Biotech – Transforming Cancer Care 1. As of March 31, 2025 Pioneer and Leader in CAR - T Therapy Revolution 2,600 Employees 450+ Focused on R&D Stand - alone with End - to - end Capabilities Partnerships
Slide 4: CARVYKTI: Proven Leader on the Path to Cure
4 CARVYKTI ® Proven Leader on the Path to Cure First and only CAR - T cell therapy demonstrating superior OS vs SoC in Multiple Myeloma >6,500 patients treated worldwide Strongest CAR - T launch to date with industry leading 79% NTS CAGR since launch 1 Positive opinion from CHMP 2 for inclusion of C
Slide 5: Multiple Myeloma: Blood Cancer with a High Unmet Need
5 Multiple Myeloma Blood Cancer with a High Unmet Need CI, confidence interval; PI, Proteasome Inhibitor; IMiD , immunomodulatory drug; MM, multiple myeloma; OS, overall survival 1. Leukemia & Lymphoma Society: https://www.lls.org/sites/default/files/2024 - 09/PS80_FactsBook_2024.pdf. Accessed Janua
Slide 6: Legend and J&J Global Collaboration
6 Legend and J&J Global Collaboration Worldwide Collaboration and License Agreement to Develop and Commercialize Cilta - cel with J&J, the #1 Global Multiple Myeloma Market Leader 50/50 United States Europe 50/50 Japan 50/50 Working Together to Realize CARVYKTI’S $5B+ Potential
Slide 7: CARVYKTI - First in MM to Achieve OS Benefit vs SOC
7 CARVYKTI ® - First CAR - T in MM to Achieve OS Benefit vs SOC Gold Standard for Oncology Trials • O ne - time infusion significantly prolonged overall survival and improved quality of life 1 • 45% reduction in risk of death with CARVYKTI ® vs SOC in patients w i th l enalidomide - refractory MM af
Slide 8: Maximizing Our CARVYKTI Market Leadership
8 MAXIMIZING OUR CARVYKTI MARKET LEADERSHIP
Slide 9: A New Standard for Launches
9 Data Source: Companies' public filings. A New Standard for CAR - T Launches CARVYKTI ® - INDUSTRY LEADING EARLY LAUNCH PERFORMANCE FIRST TWELVE QUARTERS OUTPERFORMING HISTORICAL CAR - T LAUNCHES Quarters since launch Quarterly sales ($MM) 0 50 100 150 200 250 300 350 400 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9
Slide 10: CARVYKTI Uptake Continues: Net Trade Sales
10 10 +135% growth vs Q1’24 CARVYKTI ® Net Trade Sales ($MM) U.S. OUS 24 55 55 70 114 140 146 140 167 258 304 318 0 0 0 2 3 12 13 16 20 27 31 51 0 50 100 150 200 250 300 350 400 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 → U.S. QoQ growth of 5% pr
Slide 11: CARTITUDE Earlier Line Studies
11 CARTITUDE - 2 1 CARTITUDE - 5 2 CARTITUDE - 6 3 Earlier Line Studies Another Opportunity to Change the Treatment Paradigm NCT04133636 • Global, multi - cohort study • Phase II open - label study of cilta - cel in various clinical settings • Active, enrolling NCT04923893 • Global, randomized, regi
Slide 12: Unlocking the Blockbuster Global Market Opportunity
12 Unlocking the Blockbuster Global Market Opportunity MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR CAR - T THERAPY Frontline : ~52k patients 2L to 4L: ~80k patients 5L+ : ~22k patients 1. MHLW is the Ministry of Health, Labour and Welfare in Japan. 2. ANVISA is the Brazilian Health Regulatory Agency, Agê
Slide 13: Outpatient Administration: Key Competitive Advantage
13 Outpatient Administration: Key Competitive Advantage • Extensive use of CARVYKTI in outpatient setting is a key differentiator - Unique delayed CRS 1 onset allows for outpatient administration options to best serve patient needs • Patients and caregivers prefer to leave the treatment setting for
Slide 14: Global Manufacturing Footprint
14 Global Manufacturing Footprint Expanding to Meet Growing Global Demand US FACILITIES Raritan, NJ US / EU / JP / ROW Launch/ Commercial Site for CARVYKTI ® x GMP Operational • Approval of new Raritan section expected in 2H25 Morris Plains, NJ Novartis CMO Site x Clinical production started July 20
Slide 15: US and EU CARVYKTI Supply Overview
15 US and EU CARVYKTI ® Supply Overview 1H22 2H22 1H23 2H23 1H24 2H24 1H25 2H25 1H26 2H26 1H27 2H27 2028 2029 2030 Doses Launch Facilities Expansion/ Process Optimization Raritan Slot Ramp Up Obelisc Clinical + Commercial Online Tech Lane Online CMO Online Raritan Physical Expansion Facilities Drivi
Slide 16: Building Upon CARVYKTI's Leadership Position
16 Building Upon ‘s Leadership Position 2022 2023 2024 Indication Expansion Deepening Community Penetration Preparing for 1L Use Ongoing Data Redefining Treatment Expectations in MM 4L+ Approval 2L+ Approval Continued Market Leadership 2025 2026 Established Position in MM Treatment Paradigm Since 20
Slide 17: Building Next Generation Programs
17 BUILDING NEXT GENERATION CAR - T PROGRAMS
Slide 18: Pipeline
18 *I n collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. † Phase 1 investigator - initiated trial. ‡ IND applications have been cleared by the U.S. FDA. # Subject to an exclusive license agreement with Novartis Pharma AG. The safety and efficacy of the agents and/or uses un
Slide 19: Our Differentiated R&D Approach
19 Autologous Allogeneic In Vivo Hematologic malignancies Solid tumor s Autoimmune Diseases Our Differentiated R&D Approach Potential best - in - class proprietary technology platforms and end - to - end capability Armoring strategy for solid tumors Multiple armored CAR - T strategies to overcome ch
Slide 20: In Vivo Delivery
20 In Vivo Delivery A next generation approach to off - the - shelf CAR - T In Vivo CAR - T Therapy Reprogramming immune cells directly in the body through direct infusion, eliminating the need for ex vivo cell engineering and manufacturing • Better CAR - T cell fitness • Off - the - shelf therapy •
Slide 21: Legend and Novartis Collaboration
21 Legend and Novartis Collaboration Legend and Novartis have an exclusive, global license agreement to advance certain DLL3 - targeted CAR - T therapies, including LB2102, an investigational therapy for small cell lung cancer.
Slide 22: Small Cell Lung Cancer: A Large Unmet Medical Need
22 Small Cell Lung Cancer A Large Unmet Medical Need US: Incidence is ~35 ,000 1 Lung Cancer is the Second Most Diagnosed Cancer in the US 1 And the leading cause of cancer death in both men and women, accounting for ~20% of all cancer deaths 1 Accounts for ~15% of all Lung Cancer Diagnoses 1 and in
Slide 23: LB2102: Armored CAR-T Targeting DLL3 for SCLC
23 LB2102: Legend A rmored CAR - T Targeting DLL - 3 For Small Cell Lung Cancer TARGET • DLL - 3, a promising target with prevalent & homogeneous expression in SCLC (~80% positive) and other neuroendocrine tumors • Minimal to no expression in normal tissues PRECLINICAL & Clinical Development strateg
Slide 24: LB1908: CAR-T Targeting CLDN18.2
24 LB1908 (LCAR - C18S): Legend CAR - T Targeting CLDN18.2 For gastric cancer, esophageal cancer and pancreatic cancer TARGET • Claudins (CLDN) are a family of tight junction proteins 1 - CLDN18.2 is expressed in gastric cancer and pancreatic cancer 2 Clinical Development strategy • POC achieved in
Slide 25: Upcoming Anticipated Legend Milestones
25 * Novartis Pharmaceuticals Corporation Upcoming Anticipated Legend Milestones COMMERCIAL • Increasing demand and deepening penetration into the community • Outpatient program expansion • OS label update CLINICAL • Topline data in CART - 5 • Advance pipeline programs, advance two programs into IND
Slide 26: Legend is the proven leader forging the path to cure
26 is the proven leader forging the path to cure.
Slide 27: Thank You
BIOTECH THANK YOU § } ’